2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2020
Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature
Oren-Shabtai M, Kremer N, Lapidoth M, Sharon E, Atzmony L, Nosrati A, Hodak E, Mimouni D, Levi A. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature. Drugs & Aging 2020, 38: 125-136. PMID: 33230804, DOI: 10.1007/s40266-020-00823-5.Peer-Reviewed Original ResearchConceptsOlder patientsBullous pemphigoidTopical corticosteroidsCohort studyTreatment of bullous pemphigoidSide effect profileRetrospective cohort studyNational Institutes of Health databaseProspective cohort studySystematic reviewBackgroundBullous pemphigoidRandomized controlled trialsSignificant adverse effectsPartial responseSystemic corticosteroidsCase seriesTherapeutic optionsPatient selectionTreatment modalitiesAdverse eventsOlder adultsConclusionsCurrent dataPrimary outcomeSecondary outcomesUS National Institutes